<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.48750.009</object-id><label>Table 1.</label><caption><title>Summary of nanobody generation and validation.</title></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Primary selection and validation</th><th colspan="2" valign="top">Validation as intrabodies</th><th colspan="3" valign="top">Validation as immunolabels</th></tr><tr><th>Target</th><th>Phage clones selected</th><th>ELISA positives</th><th>Unique ELISA positives</th><th>COS-1 intrabody positives</th><th>Neuron intrabody positives</th><th>COS-1 IF-ICC positives</th><th>Brain IHC positives</th><th>Brain IB positives</th></tr></thead><tbody><tr><td>Homer1</td><td>180</td><td>135</td><td>39</td><td>32</td><td>12</td><td>33</td><td>25</td><td>13</td></tr><tr><td>IRSp53</td><td>160</td><td>33</td><td>17</td><td>8</td><td>3</td><td>0</td><td>0</td><td>0</td></tr><tr><td>SAPAP2</td><td>172</td><td>32</td><td>15</td><td>7</td><td>2</td><td>0</td><td>4</td><td>0</td></tr><tr><td>Gephyrin</td><td>182</td><td>78</td><td>24</td><td>9</td><td>5</td><td>0</td><td>1</td><td>2</td></tr><tr><td>AMIGO-1</td><td>173</td><td>38</td><td>18</td><td>13</td><td>5</td><td>0</td><td>0</td><td>0</td></tr></tbody></table></table-wrap>